Science Links Japan | A New Pharmacotherapy Strategy for Treating Cases of Severe Heart Failure Complicated by Pleural and Pericardial Effusions-H-ANP and PDE III Inhibitor Restored Cardiac Function and Protected Renal Function in Patients with Serious Heart Failure-

A New Pharmacotherapy Strategy for Treating Cases of Severe Heart Failure Complicated by Pleural and Pericardial Effusions-H-ANP and PDE III Inhibitor Restored Cardiac Function and Protected Renal Function in Patients with Serious Heart Failure-

Accession number;06A0524595

Title;A New Pharmacotherapy Strategy for Treating Cases of Severe Heart Failure Complicated by Pleural and Pericardial Effusions-H-ANP and PDE III Inhibitor Restored Cardiac Function and Protected Renal Function in Patients with Serious Heart Failure-

Author; OGAWA TAKUO (Sogo Kami-Iida Daiichi Byoin) ISOBE SATOSHI (Sogo Kami-Iida Daiichi Byoin) ISHIKAWA KYOSUKE (Aichi Prefectural Aichi Hospital, JPN)

Journal Title;Ther Res

Journal Code:Y0681A

ISSN:0289-8020

VOL.27;NO.6;PAGE.1183-1194(2006)

Figure&Table&Reference;FIG.9, TBL.4, REF.21

Pub. Country;Japan

Language;Japanese

Abstract;This study investigated the effects of administration of human atrial natriuretic peptide (hANP) and phosphodiesterase III inhibitor (PDE III-I) on the restoration of cardiac function and the protection of renal function in patients with serious heart failure. 32 inpatients with serious heart failure complicated by Pleural effusion (Ple) were divided into 3 groups according to ejection fraction (EF) as determined by echocardiography: Group (Gr) A (n=6); EF was 50% or higher, Gr B (n=6); EF was lower than 50%. In Gr A and Gr B, Ple was rapidly resolved after conventional treatment without hANP and PDE-I. Gr C (n=20); EF was lower than 50%. In Gr C, Ple was not rapidly resolved, also pericardial effusion was coexistent. Patients in Gr C were treated with hANP and PDE III-I in addition to conventional treatment. In all groups, cardiac function was assessed based on echocardiography and blood BNP levels. Renal function was assessed based on blood & urinary .BETA.2-microglobulin (.BETA.2MG) levels. In Gr A, neither EF nor blood BNP levels were improved with conventional treatment. A significant decrease in BNP levels was noted after treatment in Gr B & C (both p<0.01), and EF was improved. Levels of blood & urinary .BETA.2MG after treatment were elevated in Gr A. In Gr B, there was no change in both levels of blood & urinary .BETA.2MG. However in Gr C, there was a significant decrease in levels of urinary .BETA.2MG after treatment (p<0.05). Accordingly in patients with serious heart failure, a cure to reduce a renal damage at the same time is necessary for treatment of heart failure, and hANP and PDE III-I combination therapy was effective in restoring cardiac function and also effective in protecting renal function in those patients. (author abst.)

Related Articles;